{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Catalyst Pharmaceutical Partners Inc", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Muscular Dystrophy", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Jacobus Pharmaceutical Co", "name": "organizations", "rank": "6", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/02/18/health/fda-deals-setback-to-catalyst-in-race-for-drug-approval.html", "document_type": "article", "byline": {"person": [{"lastname": "TAVERNISE", "firstname": "Sabrina", "role": "reported", "organization": "", "rank": 1}], "original": "By SABRINA TAVERNISE"}, "type_of_material": "News", "multimedia": [], "section_name": "Health", "word_count": "287", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Catalyst Pharmaceuticals, vying for exclusive rights to a drug that treats a rare neuromuscular condition, received a letter saying its application was incomplete.", "pub_date": "2016-02-18T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Drug Maker Dealt Setback in Race for F.D.A. Assent", "main": "F.D.A. Deals Setback to Catalyst in Race for Drug Approval"}, "print_page": "5", "snippet": "Catalyst Pharmaceuticals, vying for exclusive rights to a drug that treats a rare neuromuscular condition, received a letter saying its application was incomplete.", "_id": "56c4c1e038f0d85d2735f49d", "slideshow_credits": null, "abstract": "Catalyst Pharmaceuticals, Florida firm in competition for approval of drug that treats rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, has setback when FDA says it requires more information before approval is granted."}